JPH0250883B2 - - Google Patents
Info
- Publication number
- JPH0250883B2 JPH0250883B2 JP57005478A JP547882A JPH0250883B2 JP H0250883 B2 JPH0250883 B2 JP H0250883B2 JP 57005478 A JP57005478 A JP 57005478A JP 547882 A JP547882 A JP 547882A JP H0250883 B2 JPH0250883 B2 JP H0250883B2
- Authority
- JP
- Japan
- Prior art keywords
- pepstatin
- ethindidine
- pharmacologically acceptable
- acid
- gastric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229950000964 pepstatin Drugs 0.000 claims abstract description 66
- 108010091212 pepstatin Proteins 0.000 claims abstract description 63
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 claims abstract description 63
- 238000011282 treatment Methods 0.000 claims abstract description 12
- KEDVUOWPLAHMLZ-UHFFFAOYSA-N 1-cyano-3-[2-[(5-methyl-1h-imidazol-4-yl)methylsulfanyl]ethyl]-2-prop-2-ynylguanidine Chemical compound CC=1NC=NC=1CSCCNC(NC#N)=NCC#C KEDVUOWPLAHMLZ-UHFFFAOYSA-N 0.000 claims abstract 3
- 229950007285 etintidine Drugs 0.000 claims abstract 3
- 208000025865 Ulcer Diseases 0.000 claims description 17
- 231100000397 ulcer Toxicity 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 15
- 230000015572 biosynthetic process Effects 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 12
- 208000008469 Peptic Ulcer Diseases 0.000 claims description 11
- 230000001079 digestive effect Effects 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 abstract description 22
- 241001465754 Metazoa Species 0.000 abstract description 21
- 102000057297 Pepsin A Human genes 0.000 abstract description 19
- 108090000284 Pepsin A Proteins 0.000 abstract description 19
- 229940111202 pepsin Drugs 0.000 abstract description 17
- 239000003485 histamine H2 receptor antagonist Substances 0.000 abstract description 8
- 230000000767 anti-ulcer Effects 0.000 abstract description 4
- 239000008139 complexing agent Substances 0.000 abstract description 3
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 229960001380 cimetidine Drugs 0.000 description 12
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 208000007107 Stomach Ulcer Diseases 0.000 description 8
- 208000000718 duodenal ulcer Diseases 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 7
- 230000027119 gastric acid secretion Effects 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 208000011906 peptic ulcer disease Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- DRLLEHPFGRESBT-UHFFFAOYSA-N 2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethyl acetate;hydron;dichloride Chemical compound Cl.Cl.C1CN(CCOC(=O)C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 DRLLEHPFGRESBT-UHFFFAOYSA-N 0.000 description 2
- BQENDLAVTKRQMS-SBBGFIFASA-L Carbenoxolone sodium Chemical compound [Na+].[Na+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCC([O-])=O)C1(C)C BQENDLAVTKRQMS-SBBGFIFASA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010053155 Epigastric discomfort Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHUZAAUGHUHIDS-ONEGZZNKSA-N Isomyristicin Chemical compound COC1=CC(\C=C\C)=CC2=C1OCO2 DHUZAAUGHUHIDS-ONEGZZNKSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010042220 Stress ulcer Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229960000530 carbenoxolone Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229960005439 propantheline bromide Drugs 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000218594 Picea pungens Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical group [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000272534 Struthio camelus Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001262 anti-secretory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000007771 core particle Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940124568 digestive agent Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 doseâresponse relationship Toxicity 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000001809 melena Anatomy 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 210000000253 proventriculus Anatomy 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000000580 secretagogue effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
ãçºæã®è©³çŽ°ãªèª¬æã
æ¬çºæã¯è¬çççµæç©ã«é¢ããã
æž©è¡åç©ã«ãããæ¶åæ§æœ°çã®æ²»çã«ãããŠã
ãã·ã³âã³ã³ãã¬ãã·ã³ã°å€ãããã¹ã¿ãã³ãšã
ã¹ã¿ãã³H2âåäœæ®æ質ããšãã³ããžã³ãåæ
æäžããã°æâ朰ç掻æ§ãåäžãæå¹æ²»çã«å¿ èŠ
ãªãšãã³ããžã³éãæžå°ãããã«ãã€ãŠãšãã³ã
ãžã³ã®å¯äœçšåŸåãæžå°ãããæ¬çºæã¯ããã¹ã¿
ãã³ãšãšãã³ããžã³ã®åææäžã«ããæž©è¡åç©ã«
ãããæ¶åæ§æœ°çã®æ²»ççšã®ãããïŒè¬å€ãå«ã
補è¬çµæç©ã«é¢ããã
ãã·ã³âã³ã³ãã¬ãã·ã³ã°å€ãããã¹ã¿ãã³ãšã
ã¹ã¿ãã³H2âåäœæ®æ質ããšãã³ããžã³ãåæ
æäžããã°æâ朰ç掻æ§ãåäžãæå¹æ²»çã«å¿ èŠ
ãªãšãã³ããžã³éãæžå°ãããã«ãã€ãŠãšãã³ã
ãžã³ã®å¯äœçšåŸåãæžå°ãããæ¬çºæã¯ããã¹ã¿
ãã³ãšãšãã³ããžã³ã®åææäžã«ããæž©è¡åç©ã«
ãããæ¶åæ§æœ°çã®æ²»ççšã®ãããïŒè¬å€ãå«ã
補è¬çµæç©ã«é¢ããã
人äœã«ãããæ¶åæ§æœ°ç圢æã®æ£ç¢ºãªåå ã¯ç¥
ãããŠããªãããèé žããã®ç æ°ã®åå ã®ïŒéèŠ
èŠçŽ ãšèããããŠãããæè¿èé žåæ³ãèç²èã®
åŽå£çŽ°èäžã«ãããã¹ã¿ãã³H2âåäœã«ãã€ãŠ
å°ãªããããçšåºŠäžä»ãããŸãããããåæ³ä¿é²
å€ã«ãã€ãŠãããèé žåæ³ããããåäœã®ç¹æ®æ®
æ質ã«ãã€ãŠæå¶ãããããšãçºç¥ãããããã©
ãã¯ïŒJ.W.ãã®Nature.236ã385â390ïŒ1972ïŒïŒ
ããªã³ãã«ã³ã ïŒR.W.ãã®J.Int.Med.Res.ïŒïŒã
86â92ïŒ1975ïŒããåããŠã§ããåžè²©ã®ãã¹ã¿ãã³
H2âåäœæ®æ質ãã·ã¡ããžã³ã¯ä»ã朰çæ²»çå€
ãšããŠåºã䜿çšãããŠããããšãã³ããžã³ïŒBL
â5641ïŒã¯ã·ã¡ããžã³ã®çŽïŒåã®å¹åããã€æ°èŠ
ã®ãã¹ã¿ãã³H2âåäœæ®æ質ã§ããããã€ãã
ãïŒR.L.ãã®Fed.Proc.ïŒ39ã768ïŒ1980ïŒãã
ãããŠããªãããèé žããã®ç æ°ã®åå ã®ïŒéèŠ
èŠçŽ ãšèããããŠãããæè¿èé žåæ³ãèç²èã®
åŽå£çŽ°èäžã«ãããã¹ã¿ãã³H2âåäœã«ãã€ãŠ
å°ãªããããçšåºŠäžä»ãããŸãããããåæ³ä¿é²
å€ã«ãã€ãŠãããèé žåæ³ããããåäœã®ç¹æ®æ®
æ質ã«ãã€ãŠæå¶ãããããšãçºç¥ãããããã©
ãã¯ïŒJ.W.ãã®Nature.236ã385â390ïŒ1972ïŒïŒ
ããªã³ãã«ã³ã ïŒR.W.ãã®J.Int.Med.Res.ïŒïŒã
86â92ïŒ1975ïŒããåããŠã§ããåžè²©ã®ãã¹ã¿ãã³
H2âåäœæ®æ質ãã·ã¡ããžã³ã¯ä»ã朰çæ²»çå€
ãšããŠåºã䜿çšãããŠããããšãã³ããžã³ïŒBL
â5641ïŒã¯ã·ã¡ããžã³ã®çŽïŒåã®å¹åããã€æ°èŠ
ã®ãã¹ã¿ãã³H2âåäœæ®æ質ã§ããããã€ãã
ãïŒR.L.ãã®Fed.Proc.ïŒ39ã768ïŒ1980ïŒãã
朰ç圢æã®åå ã«ãããèçœè³ªå解é
µçŽ ããã
ã·ã³ã®æå²ã¯å®å šã«ã¯ããã€ãããªããããã·ã³
ã¯åç©ã«çµéšçã«ããã朰çã®çºéã«äž»åœ¹ããã
ãšãããŠããããããã¯æåã®å·å®³ãããããã
ããããå£æ»çµç¹ã®ããã·ã³æ¶åã«ããããã®æ¡
倧ã«ãããã®ã§ããããããã·ã³ã¯ãã ãã«å šã
責任ããããŸãé žã¯çã¿ãçããã€æ²»çãããã
ããããšãããããã
ã·ã³ã®æå²ã¯å®å šã«ã¯ããã€ãããªããããã·ã³
ã¯åç©ã«çµéšçã«ããã朰çã®çºéã«äž»åœ¹ããã
ãšãããŠããããããã¯æåã®å·å®³ãããããã
ããããå£æ»çµç¹ã®ããã·ã³æ¶åã«ããããã®æ¡
倧ã«ãããã®ã§ããããããã·ã³ã¯ãã ãã«å šã
責任ããããŸãé žã¯çã¿ãçããã€æ²»çãããã
ããããšãããããã
ïŒïŒ ç±³åœç¹èš±ç¬¬4112234å·ã¯æ§é åŒïŒ
ããã€ãã¹ã¿ãã³H2âåäœæ®æ質ã§ãããšã
ã³ããžã³ïŒBLâ5641ïŒãçºè¡šããŠããã
ã³ããžã³ïŒBLâ5641ïŒãçºè¡šããŠããã
ïŒïŒ ãã€ã€ãŒã¹ïŒW.MãšããŒã¿ãŒãœã³ïŒW.L.
ã¯Climical Research.28ã30AïŒ1980ïŒã«ãšã
ã³ããžã³ãäžæŽ»æ§åäºæè žæœ°çããã€æ£è ã®é£
äºã§åºæãããèé žåæ³ãå¹æçã«æå¶ããã
ãšã瀺ãèšåºè©Šéšãå ±åããŠããã
ã¯Climical Research.28ã30AïŒ1980ïŒã«ãšã
ã³ããžã³ãäžæŽ»æ§åäºæè žæœ°çããã€æ£è ã®é£
äºã§åºæãããèé žåæ³ãå¹æçã«æå¶ããã
ãšã瀺ãèšåºè©Šéšãå ±åããŠããã
ïŒïŒ ãŠã¡ã¶ã¯ïŒH.ãã¯ãJ.Antibioticsã23ã
259â262ïŒ1970ïŒã«åŒïŒ ããã¡é µçŽ ããã·ã³ã®ç¹æ®ã³ã³ãã¬ãã·ã³ã°å€
ã§ãããã³ã¿ãããããããã¹ã¿ãã³ãçºè¡šã
ãŠãããããã¹ã¿ãã³ã¯å¹œéçµçŽ®ããïŒã·ãš
ã€ïŒããã¿ã®è朰ççºçãé²ããããšãããã€
ãã
259â262ïŒ1970ïŒã«åŒïŒ ããã¡é µçŽ ããã·ã³ã®ç¹æ®ã³ã³ãã¬ãã·ã³ã°å€
ã§ãããã³ã¿ãããããããã¹ã¿ãã³ãçºè¡šã
ãŠãããããã¹ã¿ãã³ã¯å¹œéçµçŽ®ããïŒã·ãš
ã€ïŒããã¿ã®è朰ççºçãé²ããããšãããã€
ãã
ïŒïŒ ãã³ããŽã€ãŒïŒO.ãã¯Gut.20ã624â628
ïŒ1979ïŒã«åäºæè žæœ°çããã€æ£è ã«ããã¹ã¿
ãã³å¯Ÿãã©ã»ãã®ïŒéç®ãããç¡äœçºèšåºè©Šéš
ã®çµæãå ±åããŠãããããã¹ã¿ãã³ãïŒæ¥ïŒ
å100mgè¬éãæäžããããã®éã¯è液ã®æ¶å
掻æ§ãïŒæ¥ã«18æéæå¶ããã«å åã§ãã€ãã
åäºæè žæœ°çã®æ²»çåã¯çååŠã«ãããŠããã¹
ã¿ãã³ãšãã©ã»ãã®éã«äœãå·®ã®ãªãããšãã
ãã€ãã
ïŒ1979ïŒã«åäºæè žæœ°çããã€æ£è ã«ããã¹ã¿
ãã³å¯Ÿãã©ã»ãã®ïŒéç®ãããç¡äœçºèšåºè©Šéš
ã®çµæãå ±åããŠãããããã¹ã¿ãã³ãïŒæ¥ïŒ
å100mgè¬éãæäžããããã®éã¯è液ã®æ¶å
掻æ§ãïŒæ¥ã«18æéæå¶ããã«å åã§ãã€ãã
åäºæè žæœ°çã®æ²»çåã¯çååŠã«ãããŠããã¹
ã¿ãã³ãšãã©ã»ãã®éã«äœãå·®ã®ãªãããšãã
ãã€ãã
ïŒïŒ ã¹ãŽãšã³ãã»ã³ïŒL.B.ãã¯Scand.J.
Gastroento.ïŒ14ã929â932ïŒ1979ïŒã«è朰çã
ãã€æ£è ã®ããã¹ã¿ãã³å¯Ÿãã©ã»ãã®ïŒéç®é
ãç¡äœçºèšåºå®éšã®çµæãå ±åããŠããããã
ã¹ã¿ãã³ãïŒæ¥ïŒå100mgè¬éã§æäžãããè
朰çã®æ²»çåã¯çåã®ãããã«ãããã¹ã¿ãã³
ã®åœ±é¿ã¯å šãèªããããªãã€ãã
Gastroento.ïŒ14ã929â932ïŒ1979ïŒã«è朰çã
ãã€æ£è ã®ããã¹ã¿ãã³å¯Ÿãã©ã»ãã®ïŒéç®é
ãç¡äœçºèšåºå®éšã®çµæãå ±åããŠããããã
ã¹ã¿ãã³ãïŒæ¥ïŒå100mgè¬éã§æäžãããè
朰çã®æ²»çåã¯çåã®ãããã«ãããã¹ã¿ãã³
ã®åœ±é¿ã¯å šãèªããããªãã€ãã
ïŒïŒ ã¹ãã©ãŠã¹ïŒR.J.ãã¯Surg.Forum.28ã
361â363ïŒ1977ïŒã«ããã¿ã«ãããã¹ãã¬ã¹æœ°
ç圢æè©Šéšã«ãããŠã·ã ããžã³åã¯ã«ã«ããã
ãœãã³ã®ããããã§ïŒåã¯ïŒæ¥ä»¥äžäºåŠçãã
ã°æœ°ç圢æã¯èããæžå°ãããšçºè¡šããŠããã
äžèšïŒè¬å€ã䜵çšããã°å ãåæ¥äºãæäžãã
åŸã«èãã朰çæžå°ãã¿ããããã«ã«ããããœ
ãã³ã¯åæ³æå¶åã¯æ¶åæå¶å€ã§ã¯ãªãããè
ç²æ¶²åæãåºæããããšã«ãã€ãŠåããã
361â363ïŒ1977ïŒã«ããã¿ã«ãããã¹ãã¬ã¹æœ°
ç圢æè©Šéšã«ãããŠã·ã ããžã³åã¯ã«ã«ããã
ãœãã³ã®ããããã§ïŒåã¯ïŒæ¥ä»¥äžäºåŠçãã
ã°æœ°ç圢æã¯èããæžå°ãããšçºè¡šããŠããã
äžèšïŒè¬å€ã䜵çšããã°å ãåæ¥äºãæäžãã
åŸã«èãã朰çæžå°ãã¿ããããã«ã«ããããœ
ãã³ã¯åæ³æå¶åã¯æ¶åæå¶å€ã§ã¯ãªãããè
ç²æ¶²åæãåºæããããšã«ãã€ãŠåããã
ïŒïŒ ããžã€ãïŒE.Zãã¯J.Pharmacol.Exp.
Ther.ïŒ210ã373â377ïŒ1979ïŒã«ããã¿ã«ãã
ãã¹ãã¬ã¹æœ°ç圢æè©Šéšã«ãããŠãã·ã¡ããžã³
ãšãããã³ããªã³ãããã€ãã®æ··åç©ã¯å ±å朰
çé²æ¢æŽ»æ§ãçããŸãã·ã¡ããžã³ãšããªããã
ãŒã€ãå¡©é žå¡©ã®æ··åç©ã¯è¿œå 朰çé²æ¢æŽ»æ§ãç
ãããšçºè¡šããŠããããããã³ããªã³ãããã€
ãïŒã¢ã³ãã³ãªã³å€ïŒãšããªããããŒã€ãå¡©é ž
å¡©ïŒãã©ã³ãã©ã€ã¶ãŒïŒã¯åã èåæ³ãæå¶ã
ãããåããã
Ther.ïŒ210ã373â377ïŒ1979ïŒã«ããã¿ã«ãã
ãã¹ãã¬ã¹æœ°ç圢æè©Šéšã«ãããŠãã·ã¡ããžã³
ãšãããã³ããªã³ãããã€ãã®æ··åç©ã¯å ±å朰
çé²æ¢æŽ»æ§ãçããŸãã·ã¡ããžã³ãšããªããã
ãŒã€ãå¡©é žå¡©ã®æ··åç©ã¯è¿œå 朰çé²æ¢æŽ»æ§ãç
ãããšçºè¡šããŠããããããã³ããªã³ãããã€
ãïŒã¢ã³ãã³ãªã³å€ïŒãšããªããããŒã€ãå¡©é ž
å¡©ïŒãã©ã³ãã©ã€ã¶ãŒïŒã¯åã èåæ³ãæå¶ã
ãããåããã
ïŒïŒ British Medical Journalã95â96ïŒ1980ïŒ
ã¯çš®ã ã®æ°æœ°çæ²»çå€ã䜿ã€ãå€æ°ã®ç 究çµæ
ãå ±åããŠãããããã·ã³æ®æ質ã«ã€ããŠã¯æ¬¡
ã®ãšããèšèŒããŠããïŒããã·ã³æ®æ質ãçšã
ãçµæã«ã¯äžæ§ã«å€±æããããããã¢ãããã¯
ãã³ã¯åäºæè žæœ°çããã€æ£è ã«äœã®å¹æã瀺
ããªãã€ãããŸãã¹ã¯ã©ã«ããšã€ãã¯è朰çã
ãã€æ£è ã«äœã®å¹æããªãã€ããè©Šéšç®¡ã§ãç
äœå ã§ãæãå¹åããããã·ã³æ®æ質ã§ããã
ãã¹ã¿ãã³ã§ããåäºæ朰çæ²»çã«ãŸãåè¡ç
ããã³é»åçããã€ãšèªããããæ£è ã®å埩åº
è¡é²æ¢ã«ãããæ£åŒã®èª¿æŽãããå®éšã«ãããŠ
å¹æãªãã€ãã
ã¯çš®ã ã®æ°æœ°çæ²»çå€ã䜿ã€ãå€æ°ã®ç 究çµæ
ãå ±åããŠãããããã·ã³æ®æ質ã«ã€ããŠã¯æ¬¡
ã®ãšããèšèŒããŠããïŒããã·ã³æ®æ質ãçšã
ãçµæã«ã¯äžæ§ã«å€±æããããããã¢ãããã¯
ãã³ã¯åäºæè žæœ°çããã€æ£è ã«äœã®å¹æã瀺
ããªãã€ãããŸãã¹ã¯ã©ã«ããšã€ãã¯è朰çã
ãã€æ£è ã«äœã®å¹æããªãã€ããè©Šéšç®¡ã§ãç
äœå ã§ãæãå¹åããããã·ã³æ®æ質ã§ããã
ãã¹ã¿ãã³ã§ããåäºæ朰çæ²»çã«ãŸãåè¡ç
ããã³é»åçããã€ãšèªããããæ£è ã®å埩åº
è¡é²æ¢ã«ãããæ£åŒã®èª¿æŽãããå®éšã«ãããŠ
å¹æãªãã€ãã
ïŒïŒ ç±³åœç¹èš±ç¬¬4101650å·ã¯æ°Žæº¶æ§è¢«èŠèãã
ã€éçé žãããªãŠã äžå¿ç²åãšãã®åšå²ã«ãã
ã¹ã¿ãã³ãšæ°Žæº¶æ§è¢«èŠèããã€é·æéäœçšãã
ããã¹ã¿ãã³æµ®éæ§ããã«ãã»ã«ãçºè¡šããŠã
ããè液å ã«ïŒé žåççŽ ãéé¢ãããããã®ã
ãã«ãã»ã«ã¯èå ãæµ®éãæ®éã®ããã¹ã¿ãã³
ãçŽïŒæéã®ããã·ã³æå¶ã§ããã«æ¯ã¹ïŒä¹è³
ïŒæéã®æå¶ã瀺ãã
ã€éçé žãããªãŠã äžå¿ç²åãšãã®åšå²ã«ãã
ã¹ã¿ãã³ãšæ°Žæº¶æ§è¢«èŠèããã€é·æéäœçšãã
ããã¹ã¿ãã³æµ®éæ§ããã«ãã»ã«ãçºè¡šããŠã
ããè液å ã«ïŒé žåççŽ ãéé¢ãããããã®ã
ãã«ãã»ã«ã¯èå ãæµ®éãæ®éã®ããã¹ã¿ãã³
ãçŽïŒæéã®ããã·ã³æå¶ã§ããã«æ¯ã¹ïŒä¹è³
ïŒæéã®æå¶ã瀺ãã
æ¬çºæã¯æœ°çæ²»çå€ã«é¢ãããæ¬çºæã®ïŒåœ¢æ
ã«ãããŠã¯ãã¹ã¿ãã³H2âåäœæ®æ質ããšãã³
ããžã³åã¯ãã®è¬çäžèš±å®¹ãããé žä»å å¡©ãšãã
ã·ã³âã³ã³ãã¬ãã·ã³ã°å€ãããã¹ã¿ãã³ã®æ··å
ç©ããæã補è¬çµæç©ã«é¢ãããä»ã®åœ¢æ ã«ãã
ãŠæ¬çºæã¯æ¶åæ§æœ°çæ²»çã®èŠããæž©è¡åç©ã«ã
ãããã®æ²»çæ³ã«é¢ããããã®æ¹æ³ã¯äžèšåç©ã«
ããã¹ã¿ãã³ã®æ¶å掻æ§æå¶éãšãšãã³ããžã³å
ãã®è¬çäžèš±å®¹ãããé žä»å å¡©ã®æœ°ç圢ææå¶æ
å¹éãåææäžããããšããæãã®ã§ãããæŽã«
æ¬çºæã®ä»ã®åœ¢æ ã«ãããŠã¯æž©è¡åç©ã®ãšãã³ã
ãžã³åã¯ãã®è¬çäžèš±å®¹ãããé žä»å å¡©ã®æœ°ç圢
ææå¶æå¹éãæäžããããšã«ããäžèšåç©ã®æ¶
åæ§æœ°çæ²»çæ³ã«ãããŠãäžèšåç©ã«ããã¹ã¿ã
ã³ã®æ¶å掻æ§æå¶éãåææäžããããšã«ããæ
å¹æ²»çã«å¿ èŠãªãšãã³ããžã³åã¯ãã®è¬çäžèš±å®¹
ãããé žä»å å¡©ã®éãæžå°ããããšããæãæ¹è¯
æ³ã«é¢ããã
ã«ãããŠã¯ãã¹ã¿ãã³H2âåäœæ®æ質ããšãã³
ããžã³åã¯ãã®è¬çäžèš±å®¹ãããé žä»å å¡©ãšãã
ã·ã³âã³ã³ãã¬ãã·ã³ã°å€ãããã¹ã¿ãã³ã®æ··å
ç©ããæã補è¬çµæç©ã«é¢ãããä»ã®åœ¢æ ã«ãã
ãŠæ¬çºæã¯æ¶åæ§æœ°çæ²»çã®èŠããæž©è¡åç©ã«ã
ãããã®æ²»çæ³ã«é¢ããããã®æ¹æ³ã¯äžèšåç©ã«
ããã¹ã¿ãã³ã®æ¶å掻æ§æå¶éãšãšãã³ããžã³å
ãã®è¬çäžèš±å®¹ãããé žä»å å¡©ã®æœ°ç圢ææå¶æ
å¹éãåææäžããããšããæãã®ã§ãããæŽã«
æ¬çºæã®ä»ã®åœ¢æ ã«ãããŠã¯æž©è¡åç©ã®ãšãã³ã
ãžã³åã¯ãã®è¬çäžèš±å®¹ãããé žä»å å¡©ã®æœ°ç圢
ææå¶æå¹éãæäžããããšã«ããäžèšåç©ã®æ¶
åæ§æœ°çæ²»çæ³ã«ãããŠãäžèšåç©ã«ããã¹ã¿ã
ã³ã®æ¶å掻æ§æå¶éãåææäžããããšã«ããæ
å¹æ²»çã«å¿ èŠãªãšãã³ããžã³åã¯ãã®è¬çäžèš±å®¹
ãããé žä»å å¡©ã®éãæžå°ããããšããæãæ¹è¯
æ³ã«é¢ããã
åç©ã®è¬çåŠçç 究ã«ãã瀺ãããŠãããšãã
ãšãã³ããžã³ã¯æ¯èŒçç¡æ¯ç©è³ªã§ããããã®ç 究
ã§ãã®æ¯æ§ç¶æ ã¯åžè²©ã®H2âæ®æ質ã·ã¡ããžã³
ã®ãããšå®è³ªçã«åããšããã€ããã·ã¡ããžã³ã
åºã人äœã«äœ¿ãããã®ã¯å¯äœçšãå°ãªãæ¯èŒçå®
å šã§ããããšã瀺ããŠãããããã¡ããæŽã«ãã®
å¯äœçšãæžå°ããããšã¯æãŸããã§ããããçš®ã
ã®åç©å®éšãããšãã³ããžã³ã¯ã·ã¡ããžã³ã®å¹å
ã®çŽ1.5ä¹è³çŽïŒåã®å¹åããããšç€ºãããŠããã
å¹åå·®ã«åºã¥ããŠãšãã³ããžã³åç¬é©éã¯ã·ã¡ã
ãžã³éçŽ1/2ä¹è³çŽ2/3ã§ããããã ãäºæ³ããã
å¯äœçšãæžå°ãããæ®éã®ã·ã¡ããžã³æäžéã¯
300mgã§ïŒæ¥ïŒåäžãããããšãã³ããžã³ã®æ®é
æäžéã¯150ä¹è³200mgã§ïŒæ¥ïŒåäžãããæ¶å掻
æ§æå¶éã®ããã¹ã¿ãã³ã®åææäžã«ãã€ãŠãšã
ã³ããžã³ã®å¿ èŠè¬éãæŽã«æžå°ããã®ãæ¬çºæã®
ç®çã§ãã€ããäžã«ç€ºããšãããã®åææåã¯ãš
ãã³ããžã³ã®åç¬çéæäžã«æ¯ã¹ãã®å¹åãïŒå
ã«å¢å ããã®ã§ãšãã³ããžã³æäžéãæŽã«ïŒåæž
å°ã§ããã
ãšãã³ããžã³ã¯æ¯èŒçç¡æ¯ç©è³ªã§ããããã®ç 究
ã§ãã®æ¯æ§ç¶æ ã¯åžè²©ã®H2âæ®æ質ã·ã¡ããžã³
ã®ãããšå®è³ªçã«åããšããã€ããã·ã¡ããžã³ã
åºã人äœã«äœ¿ãããã®ã¯å¯äœçšãå°ãªãæ¯èŒçå®
å šã§ããããšã瀺ããŠãããããã¡ããæŽã«ãã®
å¯äœçšãæžå°ããããšã¯æãŸããã§ããããçš®ã
ã®åç©å®éšãããšãã³ããžã³ã¯ã·ã¡ããžã³ã®å¹å
ã®çŽ1.5ä¹è³çŽïŒåã®å¹åããããšç€ºãããŠããã
å¹åå·®ã«åºã¥ããŠãšãã³ããžã³åç¬é©éã¯ã·ã¡ã
ãžã³éçŽ1/2ä¹è³çŽ2/3ã§ããããã ãäºæ³ããã
å¯äœçšãæžå°ãããæ®éã®ã·ã¡ããžã³æäžéã¯
300mgã§ïŒæ¥ïŒåäžãããããšãã³ããžã³ã®æ®é
æäžéã¯150ä¹è³200mgã§ïŒæ¥ïŒåäžãããæ¶å掻
æ§æå¶éã®ããã¹ã¿ãã³ã®åææäžã«ãã€ãŠãšã
ã³ããžã³ã®å¿ èŠè¬éãæŽã«æžå°ããã®ãæ¬çºæã®
ç®çã§ãã€ããäžã«ç€ºããšãããã®åææåã¯ãš
ãã³ããžã³ã®åç¬çéæäžã«æ¯ã¹ãã®å¹åãïŒå
ã«å¢å ããã®ã§ãšãã³ããžã³æäžéãæŽã«ïŒåæž
å°ã§ããã
ããã¹ã¿ãã³ãåç©ã®è¬çåŠçç 究ã«ããæ¯èŒ
çç¡æ¯ç©è³ªãšããã€ãŠããããã®LD50ã¯ãã¹ãŠ
ã®åç©é¡å®éšã«ãããŠ3000mgïŒKgãè¶ ãããã¹ãŽ
ãšã³ãã»ã³ïŒL.B.ãã®Scand.J.Gastroent.ïŒ11ã
459â463ïŒ1976ïŒããããã¯çµå£æäžã«ãããŠæ¬è³ª
çã«åžåãããªãã€ãã朰çæ¶åäžè¯çã®äººã«æ¯
æ¥700mgã®ããã¹ã¿ãã³ãïŒã±æãŸã§çµå£æäžã
ãŠãå¯äœçšã¯èªããããªãã€ãããã¹ãŽãšã³ãã»
ã³ïŒL.Bãã®äžèšæç®ïŒ1976ïŒãããã¹ã¿ãã³ã¯
ããã·ã³ã®çæãæå¶ããªãã€ãããèçœè³ªå解
掻æ§ãæ¬ ãïŒïŒïŒããã·ãžã³âããã¹ã¿ãã³è€å
ç©ã®çæã«ãã€ãŠæ¶å掻æ§ãæå¶ããã
çç¡æ¯ç©è³ªãšããã€ãŠããããã®LD50ã¯ãã¹ãŠ
ã®åç©é¡å®éšã«ãããŠ3000mgïŒKgãè¶ ãããã¹ãŽ
ãšã³ãã»ã³ïŒL.B.ãã®Scand.J.Gastroent.ïŒ11ã
459â463ïŒ1976ïŒããããã¯çµå£æäžã«ãããŠæ¬è³ª
çã«åžåãããªãã€ãã朰çæ¶åäžè¯çã®äººã«æ¯
æ¥700mgã®ããã¹ã¿ãã³ãïŒã±æãŸã§çµå£æäžã
ãŠãå¯äœçšã¯èªããããªãã€ãããã¹ãŽãšã³ãã»
ã³ïŒL.Bãã®äžèšæç®ïŒ1976ïŒãããã¹ã¿ãã³ã¯
ããã·ã³ã®çæãæå¶ããªãã€ãããèçœè³ªå解
掻æ§ãæ¬ ãïŒïŒïŒããã·ãžã³âããã¹ã¿ãã³è€å
ç©ã®çæã«ãã€ãŠæ¶å掻æ§ãæå¶ããã
朰çæ¶åäžè¯çã®æ£è
ã«ãããŠããã¹ã¿ãã³ã¯
èã®æ¶å掻æ§ãæå¶ãããèé žæ§åºŠã«ã¯åœ±é¿ãªã
ããšã蚌æãããŠãããã¹ãŽãšã³ãã»ã³ïŒL.B.ã
ã®Scand.J.Gastroent.ïŒ11ã459â463ïŒ1976ïŒãã
ãã«åããã¹ã¿ãã³H2âåäœæ®æ質ã·ã¡ããžã³
ã¯éåžžä»»æå¿é¡è ã«ãããåºç€ã®ããã³åºæ¿ãã
ãäž¡æ¹ã®èé žåæ³ãæå¶ãããããŒã©ã³ãïŒW.L.
ãã®Brit.J.Clin.Pharmacol.ïŒïŒã481â486
ïŒ1975ïŒããŸãã¯åäºæè žæœ°çããã€ãæ£è ã®åæ§
ã®èé žåæ³ãæå¶ããããã³ã°ã¹ãã¬ã¹ãG.F.ã
ã®New Englabd J.Med.ïŒ294ã801â804
ïŒ1976ïŒããšç€ºãããŠãããããã®ããã·ã³åæ³ã«
察ããå¹æã¯äœãç®ç«ããªããããã€ã³ããŒãH.
J.ããã³ããã«ããªã³Jr.ïŒR.M.ïŒã®
Gastroenterology74ã371â375ïŒ1978ïŒãããã
ã®ç 究çµæã¯ããã¹ã¿ãã³ãšã·ã¡ããžã³ã¯ã¡ãã€
ãæ©æ§ã«ãã€ãŠåããããšã瀺ããŠããããšãã³
ããžã³ã®èé žåæ³æå¶å¹æã¯ãŸãããã·ã³æŽ»æ§ã«
察ãããããç®ç«ã€ãŠå€§ããããã®ç¹ã§ã¯ãã®è¬
çåŠçæ§è³ªã¯ã·ã¡ããžã³ã®ãããšäŒŒãŠããã
èã®æ¶å掻æ§ãæå¶ãããèé žæ§åºŠã«ã¯åœ±é¿ãªã
ããšã蚌æãããŠãããã¹ãŽãšã³ãã»ã³ïŒL.B.ã
ã®Scand.J.Gastroent.ïŒ11ã459â463ïŒ1976ïŒãã
ãã«åããã¹ã¿ãã³H2âåäœæ®æ質ã·ã¡ããžã³
ã¯éåžžä»»æå¿é¡è ã«ãããåºç€ã®ããã³åºæ¿ãã
ãäž¡æ¹ã®èé žåæ³ãæå¶ãããããŒã©ã³ãïŒW.L.
ãã®Brit.J.Clin.Pharmacol.ïŒïŒã481â486
ïŒ1975ïŒããŸãã¯åäºæè žæœ°çããã€ãæ£è ã®åæ§
ã®èé žåæ³ãæå¶ããããã³ã°ã¹ãã¬ã¹ãG.F.ã
ã®New Englabd J.Med.ïŒ294ã801â804
ïŒ1976ïŒããšç€ºãããŠãããããã®ããã·ã³åæ³ã«
察ããå¹æã¯äœãç®ç«ããªããããã€ã³ããŒãH.
J.ããã³ããã«ããªã³Jr.ïŒR.M.ïŒã®
Gastroenterology74ã371â375ïŒ1978ïŒãããã
ã®ç 究çµæã¯ããã¹ã¿ãã³ãšã·ã¡ããžã³ã¯ã¡ãã€
ãæ©æ§ã«ãã€ãŠåããããšã瀺ããŠããããšãã³
ããžã³ã®èé žåæ³æå¶å¹æã¯ãŸãããã·ã³æŽ»æ§ã«
察ãããããç®ç«ã€ãŠå€§ããããã®ç¹ã§ã¯ãã®è¬
çåŠçæ§è³ªã¯ã·ã¡ããžã³ã®ãããšäŒŒãŠããã
äžèšè©Šéšã«ãããŠ0.75N HCl1.0mlãçµå£ç¹æ»Ž
æ³šå ¥ããŠããã¿ã«çããèã®ãã ããäºããšãã³
ããžã³åã¯ãšãã³ããžã³ãšããã¹ã¿ãã³ã§åŠçã
ãããã¿ã«ããããã ããšæ¯èŒããã
æ³šå ¥ããŠããã¿ã«çããèã®ãã ããäºããšãã³
ããžã³åã¯ãšãã³ããžã³ãšããã¹ã¿ãã³ã§åŠçã
ãããã¿ã«ããããã ããšæ¯èŒããã
å®éšæ³
èã®ãã ããããããããããŒããã®æ¹æ³
ãGastroenterology.77ã433â443ïŒ1979ïŒããä¿®æ£
ããŠè¡ãªã€ããäœé280â300ïœã®ãã³ã°ãšãã³ãº
æé·éããã¿ïŒããŠãŒãšãŒã¯å·ãã¢ã«ãã³ã®ãã«
ãŒã¹ãã«ãŒã¹èŸ²å ŽïŒã䜿ã€ããåç©ãåã ã®ãã
ã«å ¥ãè©Šéšåé£ç©ãšæ°Žããããã24æéãš18æé
äžããªãã€ããç¿æ¥åç©ã«ãšãã³ããžã³ãçµå£æ
äžã30ååŸã«ã¬ãŽã¢ãŒãžã«ãã€ãŠèäžã«0.75N
HCl1.0mlãç¹æ»Žããããšãã³ããžã³ãšããã¹ã¿
ãã³ã®æ··åç©ã§åŠçãããåç©ã¯å¡©é žæäžã®30å
åã«ãšãã³ããžã³ãåããŸã10ååã«ããã¹ã¿ã
ã³ã®äžå®éïŒ20mgïŒKgçµå£ïŒãåãããåºé¡äººã
ã®å®éšå®€ã«ããã以åã®ç 究ã¯ããã¹ã¿ãã³ã®ã
ã®è¬éïŒ20mgïŒKgçµå£ïŒã¯å®å šã«ããã·ã³æŽ»æ§ã
æå¶ã18æé幜éçµçŽ®ããããã¿ã®æœ°ç圢æãæ
å¶ããããšã瀺ãããHCl液ãäžããŠïŒæéåŸïŒŽ
â61 ãå®æ¥œæ»æº¶æ¶²ïŒãã·ãšãã«ã©ãã©ããªãŒãº
ã³ãªãã¬ã€ã·ãšã³ïŒ0.2mlãè ¹è å 泚å°ããŠåç©
ã殺ããã
ãGastroenterology.77ã433â443ïŒ1979ïŒããä¿®æ£
ããŠè¡ãªã€ããäœé280â300ïœã®ãã³ã°ãšãã³ãº
æé·éããã¿ïŒããŠãŒãšãŒã¯å·ãã¢ã«ãã³ã®ãã«
ãŒã¹ãã«ãŒã¹èŸ²å ŽïŒã䜿ã€ããåç©ãåã ã®ãã
ã«å ¥ãè©Šéšåé£ç©ãšæ°Žããããã24æéãš18æé
äžããªãã€ããç¿æ¥åç©ã«ãšãã³ããžã³ãçµå£æ
äžã30ååŸã«ã¬ãŽã¢ãŒãžã«ãã€ãŠèäžã«0.75N
HCl1.0mlãç¹æ»Žããããšãã³ããžã³ãšããã¹ã¿
ãã³ã®æ··åç©ã§åŠçãããåç©ã¯å¡©é žæäžã®30å
åã«ãšãã³ããžã³ãåããŸã10ååã«ããã¹ã¿ã
ã³ã®äžå®éïŒ20mgïŒKgçµå£ïŒãåãããåºé¡äººã
ã®å®éšå®€ã«ããã以åã®ç 究ã¯ããã¹ã¿ãã³ã®ã
ã®è¬éïŒ20mgïŒKgçµå£ïŒã¯å®å šã«ããã·ã³æŽ»æ§ã
æå¶ã18æé幜éçµçŽ®ããããã¿ã®æœ°ç圢æãæ
å¶ããããšã瀺ãããHCl液ãäžããŠïŒæéåŸïŒŽ
â61 ãå®æ¥œæ»æº¶æ¶²ïŒãã·ãšãã«ã©ãã©ããªãŒãº
ã³ãªãã¬ã€ã·ãšã³ïŒ0.2mlãè ¹è å 泚å°ããŠåç©
ã殺ããã
åç©ããèããšãåºããã®å€§ããæ²ã«ãã€ãŠå
æãéããŠå¡©æº¶æ¶²ã§æŽãé¡åŸ®é¡æ€æ»ãšãã ãèšé²
ã®æšæºäœçœ®ã«å¹³ãã«ãã³ã§ãšãããèããã©ãã€
ãæ¥è¿ã«ã¡ã©ïŒãã©ãã€ãã³ãŒãã¬ã€ã·ãšãŒïŒã§
äžãåçãããã ãèšé²ãããã¹ããèšé²ç®çã®
ããæå°é·ãïŒmmã®ãã ãã®ã¿ãèãããè朰ç
ã®çšåºŠã¯äžèšåºæºãæºè¶³ãããã ãã®æ倧é£ç¶é·
ãïŒmmåäœïŒã®åèšãååç©ã«ã€ããŠå®ãããã
ã圢æã®æå¶çïŒ ã¯ ïŒå¯Ÿç §è³Šåœ¢å€ãã ãmmïŒâïŒè©Šéš
è¬å€ãã ãmmïŒïŒïŒå¯Ÿç §è³Šåœ¢å€mmïŒÃ100 ãšããŠæ±ºå®ããã
æãéããŠå¡©æº¶æ¶²ã§æŽãé¡åŸ®é¡æ€æ»ãšãã ãèšé²
ã®æšæºäœçœ®ã«å¹³ãã«ãã³ã§ãšãããèããã©ãã€
ãæ¥è¿ã«ã¡ã©ïŒãã©ãã€ãã³ãŒãã¬ã€ã·ãšãŒïŒã§
äžãåçãããã ãèšé²ãããã¹ããèšé²ç®çã®
ããæå°é·ãïŒmmã®ãã ãã®ã¿ãèãããè朰ç
ã®çšåºŠã¯äžèšåºæºãæºè¶³ãããã ãã®æ倧é£ç¶é·
ãïŒmmåäœïŒã®åèšãååç©ã«ã€ããŠå®ãããã
ã圢æã®æå¶çïŒ ã¯ ïŒå¯Ÿç §è³Šåœ¢å€ãã ãmmïŒâïŒè©Šéš
è¬å€ãã ãmmïŒïŒïŒå¯Ÿç §è³Šåœ¢å€mmïŒÃ100 ãšããŠæ±ºå®ããã
çµæã¯äžå¯Ÿã§ãªãããŒã¿ã«ã€ããŠïœâè©Šéšãçš
ããŠåæããED50å€ã¯æäžéå¿çããŒã¿ããã
ããããåæãè±åœã±ã³ããªããžå€§åŠãã¬ã¹ïŒç
ãã€ã³ãã€ããããããåæïŒ1971ïŒããçšããŠ
èšç®ããã
ããŠåæããED50å€ã¯æäžéå¿çããŒã¿ããã
ããããåæãè±åœã±ã³ããªããžå€§åŠãã¬ã¹ïŒç
ãã€ã³ãã€ããããããåæïŒ1971ïŒããçšããŠ
èšç®ããã
ãšãã³ããžã³ïŒããªã¹ãã«ãã€ã€ãŒç€Ÿã®ããªã¹
ãã«ç 究æå»è¬ååŠç 究éšåæïŒãïŒåœéã®HCl
äžã«æº¶è§£ãNaOHã§PH5.5ãšãããããã¹ã¿ãã³
ïŒäžæ補è¬(æ ª)ïŒãæ°æ»Žã®ããŠã€ãŒã³80ïŒã¢ãã©ã¹ã±
ãã«ã«ã€ã³ãã¹ããªãŒãºïŒãšå質åããŠããã¹ã¿
ãã³ã®æ°Žäžæžæ¿æ¶²ãã€ãã€ããã¬ãŽã¢ãŒãžã«ãã€
ãŠäž¡ååç©ã®ïŒmlïŒKgéãçµå£æäžããã
ãã«ç 究æå»è¬ååŠç 究éšåæïŒãïŒåœéã®HCl
äžã«æº¶è§£ãNaOHã§PH5.5ãšãããããã¹ã¿ãã³
ïŒäžæ補è¬(æ ª)ïŒãæ°æ»Žã®ããŠã€ãŒã³80ïŒã¢ãã©ã¹ã±
ãã«ã«ã€ã³ãã¹ããªãŒãºïŒãšå質åããŠããã¹ã¿
ãã³ã®æ°Žäžæžæ¿æ¶²ãã€ãã€ããã¬ãŽã¢ãŒãžã«ãã€
ãŠäž¡ååç©ã®ïŒmlïŒKgéãçµå£æäžããã
è©Šéšçµæ
éåŠçããã¿ã«HClãç¹æ»Žããå Žåé·ãïŒâ10
mmãå·ŸïŒâïŒmmã®é·ã垯ç¶ã®ã²ã©ãèãã ããç
ããããã®ãã ãã¯äž»ãšããŠã³ãŒãã¹ïŒé žãšãã
ã·ã³ãåæ³ããèéšåïŒã«ããããæŽã¯ã²ã©ãã¯
䟵ãããŠããããŸãåèã«ã¯ããã¯èªããããªã
ã€ãããããã®çºèŠã¯ãã®æ¹æ³ã®åãã®èšè¿°ã®ã
ããŒããã®å ±åãšåãã§ããã
mmãå·ŸïŒâïŒmmã®é·ã垯ç¶ã®ã²ã©ãèãã ããç
ããããã®ãã ãã¯äž»ãšããŠã³ãŒãã¹ïŒé žãšãã
ã·ã³ãåæ³ããèéšåïŒã«ããããæŽã¯ã²ã©ãã¯
䟵ãããŠããããŸãåèã«ã¯ããã¯èªããããªã
ã€ãããããã®çºèŠã¯ãã®æ¹æ³ã®åãã®èšè¿°ã®ã
ããŒããã®å ±åãšåãã§ããã
HClç¹æ»Žåã«ãšãã³ããžã³17.5ã35ã70åã¯
140mgïŒKgæäžéã§äºãåŠçããã°è¬éã«çžåœã
ãŠèãã ããæžå°ããããšãã³ããžã³ã®äžèšéã«
ããã¹ã¿ãã³20mgïŒKgãå ããŠäºåŠçãããšãšã
ã³ããžã³17.5ã35ããã³70mgïŒKgéã«ããããšã
ã³ããžã³ã®æå¶å¹æãèããåäžãããããã¹ã¿
ãã³ãš140mgïŒKgã®ãšãã³ããžã³ãäºåŠçã«äœ¿çš
ããå Žåã¯ãšãã³ããžã³åç¬ã®å Žåã«å¯Ÿãæ®ãã©
æå¶å¹æã¯åäžããªãã€ããå³ïŒã¯ãšãã³ããžã³
åç¬ãšãšãã³ããžã³ãã©ã¹ããã¹ã¿ãã³ã®åæäž
ã¬ãã«ã«ãããŠããããå¯Ÿç §ããã¿ïŒäºåŠçããª
ãïŒãšæ¯ã¹ãèã®ãã ãæžå°çãå³ç€ºããŠããã
140mgïŒKgæäžéã§äºãåŠçããã°è¬éã«çžåœã
ãŠèãã ããæžå°ããããšãã³ããžã³ã®äžèšéã«
ããã¹ã¿ãã³20mgïŒKgãå ããŠäºåŠçãããšãšã
ã³ããžã³17.5ã35ããã³70mgïŒKgéã«ããããšã
ã³ããžã³ã®æå¶å¹æãèããåäžãããããã¹ã¿
ãã³ãš140mgïŒKgã®ãšãã³ããžã³ãäºåŠçã«äœ¿çš
ããå Žåã¯ãšãã³ããžã³åç¬ã®å Žåã«å¯Ÿãæ®ãã©
æå¶å¹æã¯åäžããªãã€ããå³ïŒã¯ãšãã³ããžã³
åç¬ãšãšãã³ããžã³ãã©ã¹ããã¹ã¿ãã³ã®åæäž
ã¬ãã«ã«ãããŠããããå¯Ÿç §ããã¿ïŒäºåŠçããª
ãïŒãšæ¯ã¹ãèã®ãã ãæžå°çãå³ç€ºããŠããã
å³ïŒã«ç€ºãããããŒã¿ãååž°åæã«ãã€ãŠåæ
ããå Žåãšãã³ããžã³ã«å¯Ÿããå¿çã¯çŽç·çã§ã
ããŸãããã¹ã¿ãã³ã®æ·»å ã¯è¬å€å¿çãå¹³è¡ã«å·Š
ãžç§»è¡ãããããšã瀺ããŠããããããããŒã¿ã¯
å³ïŒã«ç€ºãããŠãããå³ïŒãããšãã³ããžã³åç¬
ããã³ãšãã³ããžã³âããã¹ã¿ãã³ã®çµåãã®
ED50å€ã¯ãããã62mgïŒKgãš28mgïŒKgãšãªãã
ãšãã³ããžã³âããã¹ã¿ãã³æ··åç©ã®å¹åããšã
ã³ããžã³åç¬ã®å¹åã®ïŒå以äžã§ããããšããã
ã€ãã
ããå Žåãšãã³ããžã³ã«å¯Ÿããå¿çã¯çŽç·çã§ã
ããŸãããã¹ã¿ãã³ã®æ·»å ã¯è¬å€å¿çãå¹³è¡ã«å·Š
ãžç§»è¡ãããããšã瀺ããŠããããããããŒã¿ã¯
å³ïŒã«ç€ºãããŠãããå³ïŒãããšãã³ããžã³åç¬
ããã³ãšãã³ããžã³âããã¹ã¿ãã³ã®çµåãã®
ED50å€ã¯ãããã62mgïŒKgãš28mgïŒKgãšãªãã
ãšãã³ããžã³âããã¹ã¿ãã³æ··åç©ã®å¹åããšã
ã³ããžã³åç¬ã®å¹åã®ïŒå以äžã§ããããšããã
ã€ãã
åç©å®éšã§ããã¹ã¿ãã³ã®90ïŒ
以äžã72æé以
å ã«å€§äŸ¿ã«ãã***ãããããšãããã€ãã®ã§ã
ãã®ååç©ã¯çµå£æäžåŸæ®ãã©äœãåžåãããª
ããæ ã«ããã¹ã¿ãã³çµå£æäžåŸã®èçœè³ªå解掻
æ§ã®æå¶ã¯äž»ãšããŠãã®ååç©ã®å±éšçå¹æã«ã
ããã®ã§ããã
å ã«å€§äŸ¿ã«ãã***ãããããšãããã€ãã®ã§ã
ãã®ååç©ã¯çµå£æäžåŸæ®ãã©äœãåžåãããª
ããæ ã«ããã¹ã¿ãã³çµå£æäžåŸã®èçœè³ªå解掻
æ§ã®æå¶ã¯äž»ãšããŠãã®ååç©ã®å±éšçå¹æã«ã
ããã®ã§ããã
æ¬çºæã®æ倧å©çãããããã«ã¯ããã¹ã¿ãã³
ã®è¬éãå®çšãšããŠïŒæ¥äœé·ãèããã·ã³æŽ»æ§ã
å®è³ªçã«å®å šã«æå¶ããæ§ãªéã§ããããšãæãŸ
ãããããã¹ã¿ãã³ãïŒæ¥ïŒå100mgæäžéã§æœ°
çæ£è ã«æäžïŒé£åŸãé£äºïŒæéåŸããã³å°±å¯
æïŒããå Žåã«ããã·ã³æŽ»æ§ã¯ïŒæ¥18æéæå¶ã
ããã
ã®è¬éãå®çšãšããŠïŒæ¥äœé·ãèããã·ã³æŽ»æ§ã
å®è³ªçã«å®å šã«æå¶ããæ§ãªéã§ããããšãæãŸ
ãããããã¹ã¿ãã³ãïŒæ¥ïŒå100mgæäžéã§æœ°
çæ£è ã«æäžïŒé£åŸãé£äºïŒæéåŸããã³å°±å¯
æïŒããå Žåã«ããã·ã³æŽ»æ§ã¯ïŒæ¥18æéæå¶ã
ããã
æ¬çºæã®å¥œãŸããïŒå®æœæ
æ§ã«ãããŠãããã¹
ã¿ãã³ã®çŽ100mgæäžéãïŒæ¥ïŒåæäžãããä»
ã®å¥œãŸããå®æœæ æ§ã«ãããŠã¯æäžçŽ175mgãã€
ã®ããã¹ã¿ãã³ãïŒæ¥ïŒåæäžãããæŽã«ä»ã®å¥œ
ãŸããå®æœæ æ§ã«ãããŠã¯ç±³åœç¹èš±ç¬¬4101650å·
ã«èšèŒã®ãšããããã¹ã¿ãã³ãæµ®éæ§ããã«ãã»
ã«ã®åœ¢ã§æäžãããããã¹ã¿ãã³æµ®éæ§ããã«ã
ã»ã«ã¯éåžžã®ããã¹ã¿ãã³ããçŽïŒâïŒåé·æé
ããã·ã³ãæå¶ããããŸãäŸãã°ããã¹ã¿ãã³çŽ
100mgãå«ãæµ®éæ§ããã«ãã»ã«æäžéãïŒæ¥ïŒ
åæäžã§ããã
ã¿ãã³ã®çŽ100mgæäžéãïŒæ¥ïŒåæäžãããä»
ã®å¥œãŸããå®æœæ æ§ã«ãããŠã¯æäžçŽ175mgãã€
ã®ããã¹ã¿ãã³ãïŒæ¥ïŒåæäžãããæŽã«ä»ã®å¥œ
ãŸããå®æœæ æ§ã«ãããŠã¯ç±³åœç¹èš±ç¬¬4101650å·
ã«èšèŒã®ãšããããã¹ã¿ãã³ãæµ®éæ§ããã«ãã»
ã«ã®åœ¢ã§æäžãããããã¹ã¿ãã³æµ®éæ§ããã«ã
ã»ã«ã¯éåžžã®ããã¹ã¿ãã³ããçŽïŒâïŒåé·æé
ããã·ã³ãæå¶ããããŸãäŸãã°ããã¹ã¿ãã³çŽ
100mgãå«ãæµ®éæ§ããã«ãã»ã«æäžéãïŒæ¥ïŒ
åæäžã§ããã
æ¬çºæã«çšãããšãã³ããžã³ã®æäžéã¯çŽ50ä¹
è³çŽ150mgã§ïŒæ¥ïŒâïŒåïŒäŸãã°é£åŸããã³å°±
å¯æïŒäžãããæ¬çºæã®æã奜ãŸãããšãã³ããž
ã³æäžéã¯çŽ75ä¹è³çŽ100mgã§ïŒæ¥ïŒåäžããã
è³çŽ150mgã§ïŒæ¥ïŒâïŒåïŒäŸãã°é£åŸããã³å°±
å¯æïŒäžãããæ¬çºæã®æã奜ãŸãããšãã³ããž
ã³æäžéã¯çŽ75ä¹è³çŽ100mgã§ïŒæ¥ïŒåäžããã
æ¬çºæã®å©çãããããã«å¿
ããããšãã³ããž
ã³ãšããã¹ã¿ãžã³ãåäžæçšåœ¢æ ã«ç©ççã«æ··å
ããå¿ çšã®ãªãããšã¯ãã®æè¡åéã®ç¥èããã
ã®ã«ã¯èªããããã§ããããïŒæŽ»æ§æåãå¥ã ã«
ãšã€ãŠãããã®ã¿ãªãããïŒæåã®ã¡ãã€ãæè¬
æ¹æ³ã§äžããããšããã§ãããããã¹ã¿ãã³ã¯è
ã®å±éšäœçšã«ãã€ãŠãã®å¹æãäžããŸãçµå£æäž
ããå¿ èŠããããããšãã³ããžã³ã¯çµå£åã¯éçµ
å£æäžã§ãããããã䟿å®äžæ®éãšãã³ããžã³ã¯
çµå£æäžããã®ãããã
ã³ãšããã¹ã¿ãžã³ãåäžæçšåœ¢æ ã«ç©ççã«æ··å
ããå¿ çšã®ãªãããšã¯ãã®æè¡åéã®ç¥èããã
ã®ã«ã¯èªããããã§ããããïŒæŽ»æ§æåãå¥ã ã«
ãšã€ãŠãããã®ã¿ãªãããïŒæåã®ã¡ãã€ãæè¬
æ¹æ³ã§äžããããšããã§ãããããã¹ã¿ãã³ã¯è
ã®å±éšäœçšã«ãã€ãŠãã®å¹æãäžããŸãçµå£æäž
ããå¿ èŠããããããšãã³ããžã³ã¯çµå£åã¯éçµ
å£æäžã§ãããããã䟿å®äžæ®éãšãã³ããžã³ã¯
çµå£æäžããã®ãããã
æ¬çºæã¯æ¶åæ§æœ°çæ²»çãå¿
èŠãšããæž©è¡åç©
ã®æ¶åæ§æœ°çæ²»çæ³ãæäŸãããã®ã§ããã®æ¹æ³
ã¯äžèšåç©ã«ããã¹ã¿ãã³ã®æ¶å掻æ§æå¶éãšãš
ãã³ããžã³åã¯è£œè¬äžèš±å®¹ããããã®é žä»å å¡©ã®
朰ç圢ææå¶æå¹éãåææäžããããšããæã
ã®ã§ããã人ã«å¯Ÿãããšãã³ããžã³ã®å¥œãŸããæ
äžéã¯ïŒæ¥ïŒåã¯ïŒåã奜ãŸããã¯ïŒåã«çŽ50ä¹
è³çŽ150mgãæã奜ãŸããã¯çŽ75ä¹è³çŽ100mgãäž
ããã®ã§ãããããã¹ã¿ãã³ã®äººã«å¯Ÿãã奜ãŸã
ãæäžéã¯ïŒæ¥çŽïŒåæäžã®å Žåã®çŽ100mgãã
ïŒæ¥çŽïŒåã®å Žåã®çŽ175mgãŸã§ã§ãããããã
æ¬çºæã®å¥œãŸããå®æœæ æ§ã«ãããŠãããã¹ã¿ã
ã³ãããã¹ã¿ãã³æµ®éæ§ããã«ãã»ã«ã®åœ¢ã§ãã
å Žåã®å¥œãŸããæäžéã¯ããã¹ã¿ãã³çŽ100mgã
å«ãããã«ãã»ã«ãïŒæ¥çŽïŒåæäžããéã§ã
ãã
ã®æ¶åæ§æœ°çæ²»çæ³ãæäŸãããã®ã§ããã®æ¹æ³
ã¯äžèšåç©ã«ããã¹ã¿ãã³ã®æ¶å掻æ§æå¶éãšãš
ãã³ããžã³åã¯è£œè¬äžèš±å®¹ããããã®é žä»å å¡©ã®
朰ç圢ææå¶æå¹éãåææäžããããšããæã
ã®ã§ããã人ã«å¯Ÿãããšãã³ããžã³ã®å¥œãŸããæ
äžéã¯ïŒæ¥ïŒåã¯ïŒåã奜ãŸããã¯ïŒåã«çŽ50ä¹
è³çŽ150mgãæã奜ãŸããã¯çŽ75ä¹è³çŽ100mgãäž
ããã®ã§ãããããã¹ã¿ãã³ã®äººã«å¯Ÿãã奜ãŸã
ãæäžéã¯ïŒæ¥çŽïŒåæäžã®å Žåã®çŽ100mgãã
ïŒæ¥çŽïŒåã®å Žåã®çŽ175mgãŸã§ã§ãããããã
æ¬çºæã®å¥œãŸããå®æœæ æ§ã«ãããŠãããã¹ã¿ã
ã³ãããã¹ã¿ãã³æµ®éæ§ããã«ãã»ã«ã®åœ¢ã§ãã
å Žåã®å¥œãŸããæäžéã¯ããã¹ã¿ãã³çŽ100mgã
å«ãããã«ãã»ã«ãïŒæ¥çŽïŒåæäžããéã§ã
ãã
æ¬çºæã¯ãŸãæž©è¡åç©ã«ãšãã³ããžã³åã¯ãã®
è¬çäžèš±å®¹ãããé žä»å å¡©ã®æœ°ç圢ææå¶æå¹é
ãæäžããæ²»çæ³ã«ãããŠãããã¹ã¿ãã³ã®æ¶å
掻æ§æå¶éãåææäžããããšã«ãããšãã³ããž
ã³å¿ èŠéãæžå°ããããšã«ããæãæ¹è¯æ³ãæäŸ
ããã®ã§ããã人ã«å¯Ÿããããã¹ã¿ãã³ã®å¥œãŸã
ãè¬éããã³ããã¹ã¿ãã³æµ®éæ§ããã«ãã»ã«ã®
奜ãŸããæäžéã¯åç¯ã«èšèŒã®ãšããã§ããã
è¬çäžèš±å®¹ãããé žä»å å¡©ã®æœ°ç圢ææå¶æå¹é
ãæäžããæ²»çæ³ã«ãããŠãããã¹ã¿ãã³ã®æ¶å
掻æ§æå¶éãåææäžããããšã«ãããšãã³ããž
ã³å¿ èŠéãæžå°ããããšã«ããæãæ¹è¯æ³ãæäŸ
ããã®ã§ããã人ã«å¯Ÿããããã¹ã¿ãã³ã®å¥œãŸã
ãè¬éããã³ããã¹ã¿ãã³æµ®éæ§ããã«ãã»ã«ã®
奜ãŸããæäžéã¯åç¯ã«èšèŒã®ãšããã§ããã
æ¬çºæã«ãã€ãŠãŸãããã¹ã¿ãã³ã®æ¶å掻æ§æ
å¶éãšãšãã³ããžã³åã¯ãã®è¬çäžèš±å®¹ãããé ž
ä»å å¡©ã®æœ°ç圢ææå¶æå¹éããã³è¬çäžèš±å®¹ã
ããæ äœããæãæ¶åæ§æœ°çæ²»çã«æçšãªåäœæ
äžåœ¢æ ã®è£œè¬çµæç©ãæäŸãããã奜ãŸããå®æœ
æ æ§ã«ãããŠåäœæäžåœ¢æ ã¯çŽ50ä¹è³çŽ150mgã
奜ãŸããã¯çŽ75ä¹è³çŽ100mgã®ãšãã³ããžã³ãšçŽ
100ä¹è³175mgã®ããã¹ã¿ãã³ãå«ãã§ããã
å¶éãšãšãã³ããžã³åã¯ãã®è¬çäžèš±å®¹ãããé ž
ä»å å¡©ã®æœ°ç圢ææå¶æå¹éããã³è¬çäžèš±å®¹ã
ããæ äœããæãæ¶åæ§æœ°çæ²»çã«æçšãªåäœæ
äžåœ¢æ ã®è£œè¬çµæç©ãæäŸãããã奜ãŸããå®æœ
æ æ§ã«ãããŠåäœæäžåœ¢æ ã¯çŽ50ä¹è³çŽ150mgã
奜ãŸããã¯çŽ75ä¹è³çŽ100mgã®ãšãã³ããžã³ãšçŽ
100ä¹è³175mgã®ããã¹ã¿ãã³ãå«ãã§ããã
æ¬æ现æžã§çšãããšãã³ããžã³ã®è¬çäžèš±å®¹ã
ããé žä»å å¡©ãšã¯ãšãã³ããžã³ã®è¬çäžèš±å®¹ãã
ãææ©åã¯ç¡æ©é žãšã®ïŒå¡©åã¯ïŒå¡©ãæå³ããã
ãã®é žé¡ã¯ããç¥ãããŠãããå¡©é žãèåæ°ŽçŽ
é žãç¡«é žãã¹ã«ãã¢ãã³é žãããé žãç¡é žããã¬
ã€ã³é žãããã«é žããã¯ãé žãèé žãå®æ¯éŠé žã
ã¡ã¿ã³ã¹ã«ãã³é žããšã¿ã³ãžã¹ã«ãã³é žãé ¢é žã
ããããªã³é žãé ç³é žããããé žãã«ã³ãã¢ãŒã¹
ã«ãã³é žçããããå¡©ã¯ãã®æè¡åéã§æ¢ç¥ã®æ¹
æ³ã«ããã€ããããã
ããé žä»å å¡©ãšã¯ãšãã³ããžã³ã®è¬çäžèš±å®¹ãã
ãææ©åã¯ç¡æ©é žãšã®ïŒå¡©åã¯ïŒå¡©ãæå³ããã
ãã®é žé¡ã¯ããç¥ãããŠãããå¡©é žãèåæ°ŽçŽ
é žãç¡«é žãã¹ã«ãã¢ãã³é žãããé žãç¡é žããã¬
ã€ã³é žãããã«é žããã¯ãé žãèé žãå®æ¯éŠé žã
ã¡ã¿ã³ã¹ã«ãã³é žããšã¿ã³ãžã¹ã«ãã³é žãé ¢é žã
ããããªã³é žãé ç³é žããããé žãã«ã³ãã¢ãŒã¹
ã«ãã³é žçããããå¡©ã¯ãã®æè¡åéã§æ¢ç¥ã®æ¹
æ³ã«ããã€ããããã
æ¬çºæã®å®æœã«åœããšãã³ããžã³ãšããã¹ã¿ã
ã³ãåã¯ãããäž¡è ãå«ã補è¬çµæç©ã®æäžã«ã¯
çš®ã ã®è£œè¬åœ¢æ ã䜿çšã§ãããæ ã«åºäœæ äœã䜿
çšãããªãã°èª¿åç©ã¯é å€ãšããããšãã§ããç²
æ«åã¯ãã¬ããç¶ã§ç¡¬è³ªãŒã©ãã³ã«ãã»ã«ã«å ¥ã
ãããšãã§ãåã¯ãããŒããå£è é ãšããããšã
ã§ããã液äœæ äœã䜿çšãããªãã°ã調åç©ã¯è»
質ãŒã©ãã³ã«ãã»ã«ã®åœ¢ã«ãã·ããããä¹³æ¿æ¶²ã
æ°Žæ§åã¯éæ°Žæ§æžæ¿æ¶²ã«ã§ãããåã¯ãšãã³ããž
ã³ã®å Žåã¯æ³šå°çšç¡è溶液åã¯æžæ¿æ¶²ã«ã§ããã
ãããã®è¬çæäžåœ¢æ ã¯å ¬ç¥ã®æ¹æ³ã«ãã€ãŠè£œé
ãããã
ã³ãåã¯ãããäž¡è ãå«ã補è¬çµæç©ã®æäžã«ã¯
çš®ã ã®è£œè¬åœ¢æ ã䜿çšã§ãããæ ã«åºäœæ äœã䜿
çšãããªãã°èª¿åç©ã¯é å€ãšããããšãã§ããç²
æ«åã¯ãã¬ããç¶ã§ç¡¬è³ªãŒã©ãã³ã«ãã»ã«ã«å ¥ã
ãããšãã§ãåã¯ãããŒããå£è é ãšããããšã
ã§ããã液äœæ äœã䜿çšãããªãã°ã調åç©ã¯è»
質ãŒã©ãã³ã«ãã»ã«ã®åœ¢ã«ãã·ããããä¹³æ¿æ¶²ã
æ°Žæ§åã¯éæ°Žæ§æžæ¿æ¶²ã«ã§ãããåã¯ãšãã³ããž
ã³ã®å Žåã¯æ³šå°çšç¡è溶液åã¯æžæ¿æ¶²ã«ã§ããã
ãããã®è¬çæäžåœ¢æ ã¯å ¬ç¥ã®æ¹æ³ã«ãã€ãŠè£œé
ãããã
å³ïŒã¯ã©ããã®HClâèªçºãããèã®ãã ãã®
æå¶ã«ããããšãã³ããžã³åç¬ãšãšãã³ããžã³ãš
ããã¹ã¿ãã³ã®çµåããšã®æ¯èŒã瀺ãç·å³ã§ã
ããå³ïŒã¯ã©ããã®HClâèªçºãããèã®ãã ã
ã®æžå°ã«åãŒããšãã³ããžã³åç¬ãšãšãã³ããžã³
ãšããã¹ã¿ãã³ïŒ20mgïŒKgïŒã®çµåããšã®æäžé
ã®åœ±é¿ã瀺ãç·å³ã§ããã
æå¶ã«ããããšãã³ããžã³åç¬ãšãšãã³ããžã³ãš
ããã¹ã¿ãã³ã®çµåããšã®æ¯èŒã瀺ãç·å³ã§ã
ããå³ïŒã¯ã©ããã®HClâèªçºãããèã®ãã ã
ã®æžå°ã«åãŒããšãã³ããžã³åç¬ãšãšãã³ããžã³
ãšããã¹ã¿ãã³ïŒ20mgïŒKgïŒã®çµåããšã®æäžé
ã®åœ±é¿ã瀺ãç·å³ã§ããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ ããã¹ã¿ãã³ã®æ¶å掻æ§æå¶éãšãšãã³ããž
ã³åã¯ãã®è¬çäžèš±å®¹ãããé žä»å å¡©ã®æœ°ç圢æ
æå¶æå¹éããæãããšãç¹åŸŽãšããæ¶åæ§æœ°ç
æ²»ççšçµæç©ã ïŒ ããã¹ã¿ãã³ã®æ¶å掻æ§æå¶éãšãšãã³ããž
ã³åã¯ãã®è¬çäžèš±å®¹ãããé žä»å å¡©ã®æœ°ç圢æ
æå¶æå¹éããã³è¬çäžèš±å®¹ãããæ äœããæã
ããšãç¹åŸŽãšããåäœæäžåœ¢ã®ç¹èš±è«æ±ã®ç¯å²ç¬¬
ïŒé ã«èšèŒã®è£œè¬çµæç©ã ïŒ ãšãã³ããžã³çŽ50ä¹è³çŽ150mgãšããã¹ã¿ã
ã³çŽ100ä¹è³çŽ175mgããæãç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒ
é ã«èšèŒã®è£œè¬çµæç©ã ïŒ ããã¹ã¿ãã³ãããã¹ã¿ãã³æµ®éæ§ããã«ã
ã»ã«ã®åœ¢ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé åã¯ïŒé ã«
èšèŒã®çµæç©ã ïŒ è¬çäžèš±å®¹ãããæ äœäžã®ãšãã³ããžã³åã¯
ãã®è¬çäžèš±å®¹ãããé žä»å å¡©çŽ75ä¹è³çŽ100mg
ããã³ããã¹ã¿ãã³çŽ175mgããæãåäœæäžåœ¢
ã®ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã«èšèŒã®è£œè¬çµæç©ã ïŒ è¬çäžèš±å®¹ãããæ äœäžã®ãšãã³ããžã³åã¯
ãã®è¬çäžèš±å®¹ãããé žä»å å¡©çŽ75ä¹è³çŽ100mg
ãšããã¹ã¿ãã³æµ®éæ§ããã«ãã»ã«åœ¢æ ã®ããã¹
ã¿ãã³çŽ100mgããæãæ¶åæ§æœ°çæ²»çã«äŸ¿å©ãª
åäœæäžåœ¢ã®ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã«èšèŒã®è£œè¬
çµæç©ã
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/225,945 US4339439A (en) | 1981-01-19 | 1981-01-19 | Pharmaceutical methods and compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS57139018A JPS57139018A (en) | 1982-08-27 |
| JPH0250883B2 true JPH0250883B2 (ja) | 1990-11-05 |
Family
ID=22846923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57005478A Granted JPS57139018A (en) | 1981-01-19 | 1982-01-19 | Pharmacological method and composition |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US4339439A (ja) |
| EP (1) | EP0056973B1 (ja) |
| JP (1) | JPS57139018A (ja) |
| AT (1) | ATE26214T1 (ja) |
| CA (1) | CA1199872A (ja) |
| DE (1) | DE3275903D1 (ja) |
| DK (1) | DK16282A (ja) |
| FI (1) | FI820136L (ja) |
| GR (1) | GR75141B (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI832520L (fi) * | 1982-07-12 | 1984-01-13 | Bristol Myers Co | Farmaceutiska foerfaranden och sammansaettningar |
| US5833946A (en) * | 1995-06-06 | 1998-11-10 | Bayer Corporation | Dissemination of fungal infections: animal model and method of prophylaxis |
| WO2020130205A1 (ko) * | 2018-12-21 | 2020-06-25 | 겜ìëíêµë³ì | í©ì ìµì ì 륌 í¬íšíë ìœíì ì¡°ì±ë¬Œ ë° ê±Žê°êž°ë¥ìí |
| IT202000012370A1 (it) * | 2020-05-26 | 2021-11-26 | Drugs Minerals And Generics Italia S R L In Forma Abbreviata D M G Italia S R L | Composizione comprendente pepstatina e acido alginico o un suo sale e suo uso |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS543067A (en) * | 1977-06-03 | 1979-01-11 | Bristol Myers Co | Ulcer controlling compounds |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4101650A (en) * | 1977-04-06 | 1978-07-18 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Pepstatin floating minicapsules |
| US4112234A (en) * | 1977-08-22 | 1978-09-05 | Bristol-Myers Company | Imidazolylmethylthioethyl alkynyl guanidines |
-
1981
- 1981-01-19 US US06/225,945 patent/US4339439A/en not_active Expired - Fee Related
-
1982
- 1982-01-12 CA CA000393983A patent/CA1199872A/en not_active Expired
- 1982-01-15 FI FI820136A patent/FI820136L/fi not_active Application Discontinuation
- 1982-01-15 DK DK16282A patent/DK16282A/da not_active Application Discontinuation
- 1982-01-19 DE DE8282100354T patent/DE3275903D1/de not_active Expired
- 1982-01-19 AT AT82100354T patent/ATE26214T1/de not_active IP Right Cessation
- 1982-01-19 GR GR67046A patent/GR75141B/el unknown
- 1982-01-19 EP EP82100354A patent/EP0056973B1/en not_active Expired
- 1982-01-19 JP JP57005478A patent/JPS57139018A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS543067A (en) * | 1977-06-03 | 1979-01-11 | Bristol Myers Co | Ulcer controlling compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| FI820136L (fi) | 1982-07-20 |
| JPS57139018A (en) | 1982-08-27 |
| US4339439A (en) | 1982-07-13 |
| EP0056973A1 (en) | 1982-08-04 |
| DK16282A (da) | 1982-07-20 |
| CA1199872A (en) | 1986-01-28 |
| GR75141B (ja) | 1984-07-13 |
| DE3275903D1 (en) | 1987-05-07 |
| ATE26214T1 (de) | 1987-04-15 |
| EP0056973B1 (en) | 1987-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4316888A (en) | Method and composition of reducing pain | |
| Becht et al. | Gastroduodenal ulceration in foals | |
| KR960016582B1 (ko) | ìì¥ì¥íŽì ì¹ë£ ë° ìë°©ì© ìœì íì ì¡°ì±ë¬Œ | |
| JPH0160008B2 (ja) | ||
| EP0320551A1 (en) | Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2 receptor blockers | |
| EP0585722B1 (en) | Benzimidazole derivatives as antimicrobal agent against Campylobacter pylon | |
| EP0399051B1 (en) | Polyvalent antiinflammatory agent | |
| JPH0250883B2 (ja) | ||
| US20030216438A1 (en) | Antimicrobial agent | |
| EP0219912B1 (en) | The use of nitrofurantoin for the treatment and prophylaxis of gastrointestinal disorders | |
| Clark et al. | Clinical pharmacology of the gastrointestinal tract | |
| KR890001236B1 (ko) | ììŒì ì¡°ì±ë¬Œì ì ì¡°ë°©ë² | |
| DE2708520C2 (ja) | ||
| PT1073436E (pt) | Método melhorado para erradicação de helicobacter pylori | |
| US3995055A (en) | Method for treating peptic ulcers | |
| EP1353624B1 (en) | Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination | |
| JPH0530814B2 (ja) | ||
| KR101153571B1 (ko) | í ëí íëŒì¡ž ë° íì€í믌 ïœ2-ìì©ì²Ž êžžíì 륌 ë°°í©íì ìœ ì¡°ì±ë¬Œ | |
| US4517309A (en) | Method for the treatment of calcifying pancreatitis | |
| JP2798588B2 (ja) | æèå€ | |
| EP2123277B1 (en) | Preventive or therapeutic agent for inflammatory bowel disease | |
| JP2008255008A (ja) | æ»è现èå¢æ®æå¶å€ | |
| JP2004002454A (ja) | æ¶å管éåæå¶å€ | |
| US20230248703A1 (en) | Pharmaceutical composition comprising benzimidazole derivative compound | |
| US4942171A (en) | The compound, 6-(1-imidazolyl methyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid and salts thereof having antidiabetic activity |